Company: GANX
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001558370-25-004958
Chunk: 34

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 34
---
 Proposal 3.

Required Vote and Recommendation

In accordance with our Certificate, Bylaws and Delaware law, and as further discussed above under “Abstentions and Broker Non-Votes”, approval and adoption of this Proposal 4 requires the affirmative vote of holders of a majority of shares present in person or represented by proxy and entitled to vote thereon. Abstentions, if any, with respect to this proposal will be counted for purposes of establishing a quorum and, if a quorum is present, any abstentions, if any, will have the same practical effect as a vote against this proposal.

<div align='center'>**THE BOARD RECOMMENDS

A VOTE “FOR” PROPOSAL 4.**</div>

#### EXECUTIVE OFFICERSThe following table identifies certain information about our executive officers as of March 27, 2025. Our executive officers are appointed by, and serve at the discretion of, our Board.NameAgePrincipal PositionGene Mack​51​President, Chief Executive Officer and DirectorGianluca Fuggetta​36​Senior Vice President Finance, Principal Financial Officer​Gene MackBiographical information for Mr. Mack is included above with the director biographies under the caption “Information Regarding Director Nominees and Current Directors.”Gianluca Fuggettahas served as Senior Vice President Finance and Principal Financial Officer of Gain Therapeutics since January 2025. He joined the Company in July 2022 and has served as our Principal Accounting Officer since January 2023 and was appointed as Vice President of Finance in January 2024. He previously held the position as our Principal Financial Officer from February to April 2024. Prior to these roles, Mr. Fuggetta served as our Senior Finance Director from January to December 2023, and as Finance Director from July to December 2022. Before joining the Company, Mr. Fuggetta gained extensive experience at PwC, where he worked from September 2013 to June 2022, ultimately serving as an Assurance Manager. He holds a Bachelor’s degree in business administration from Università Cattolica del Sacro Cuore and a Master’s degree in Accounting, Auditing and Control from Università Bocconi.There are no family relationships among any of our directors or executive officers.​
EXECUTIVE COMPENSATION Compensation Overview The following tables and accompanying disclosure set forth information about the compensation earned by our named executive officers during 2024. Our named executive officers include our